YEEHAW CANDIDATES Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sergio H who wrote (10144)	8/1/2005 9:22:07 PM
From: Galirayo	Read Replies (1) of 23958

Sergio ... Pick One. stockcharts.com[w,a]dacayiay[dc][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G 07.15.05, 11:57 AM ET S&P Equity Research said. Over the next 12 months, the research firm expects sector price appreciation of about 20% and believes the sector could sustain high-teen earnings-per-share growth over the next three years. S&P Equity Research's top recommendations are Genentech (nyse: DNA - news - people ), Amylin Pharmaceuticals (nasdaq: AMLN - news - people ), Renovis (nasdaq: RNVS - news - people ) and Invitrogen (nasdaq: IVGN - news - people ), all rated at "strong buy." The research firm reiterated "strong sell" opinions on Chiron (nasdaq: CHIR - news - forbes.com What about ARIA ?? stockcharts.com[w,a]dacayiay[dc][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next